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Objective. Phosphopeptide P140 (Lupuzor) is an inhibitor of autophagy currently being evaluated in latestage clinical trials for the treatment of lupus. This study was undertaken to investigate the effect of P140 ex vivo on human T and B cells.
Methods. Human B cells, T cells, and dendritic cells were analyzed by flow cytometry and cellular assays. The expression of autophagy markers was evaluated by immunoblotting and flow cytometry. The levels of B cell receptor (BCR) signaling markers and HLA molecules were assessed by flow cytometry. Toll-like receptor ligands were screened using an assay with transfected HEK 293 cells. P140 cell entry and trafficking were measured by immunofluorescence in the presence of various inhibitors of endosomal pathways.
Results. As was previously observed after intravenous injection of the peptide in a mouse model of lupus, P140 entered human B cells by a clathrin coat-dependent endocytosis process and homed into lysosomes. The peptide displayed no direct effect on BCR signaling of memory, naive mature, transitional, and B1 cells. However, it strongly reduced the overexpression of HLA class II molecules on lupus B cells that were acting as antigenpresenting cells, down-regulated the maturation and differentiation of B cells into plasma cells, and decreased IgG secretion.
Conclusion. These findings show that P140 downregulates HLA class II overexpression in human lupus B cells, and also that P140 hampers the differentiation of B cells into autoantibody-secreting plasma cells, likely due to the resulting lack of T cell signaling and activation. This mechanism appears to switch off the downstream events leading to secretion of pathogenic autoantibodies, thus explaining the highly promising results obtained in clinical trials of P140 (Lupuzor) for the treatment of lupus.
A substantial body of evidence supports the notion that cell signaling dysfunction has a critical role in the pathogenesis and progression of systemic lupus erythematosus (SLE). In this prototypic autoimmune disease of intricate origin, immune system dysregulation seems generalized and can affect all of the compartments implicated in the innate and adaptive immune responses. Under the influence of genetic and epigenetic factors, as well as hormones and various cellular effectors, various subsets of T and B cells are generally shifted toward an overactivated state, resulting in the production of pathogenic factors, including autoantibodies, cytokines, and chemokines, Supported by the French Centre National de la Recherche Scientifique, the Laboratory of Excellence Medalis (grant ANR-10-LABX-0034; Initiative of Excellence, Strasbourg University), and R egion Alsace. Dr. Wilhelm was recipient of a predoctoral fellowship from the R egion Alsace and ImmuPharma. Dr. Wang was recipient of a postdoctoral fellowship from the University of Strasbourg Institute for Advanced Study. Drs. Faludi and Nashi's work was supported by the Canadian Arthritis Network.
which, downstream, leads to widespread inflammation and tissue damage.
The phenotype of lupus lymphocytes is analytically complex, with some characteristics that appear to be opposite in function. As naive or anergic T cells, lupus T lymphocytes are less prone to produce cytokines such as interferon-c and interleukin-2 (IL-2), whereas as activated and memory T cells, they show increased tyrosine phosphorylation of signaling intermediates, show a faster and stronger calcium flux response after T cell receptor (TCR) activation, and display higher levels of adhesion or costimulatory molecules such as CD44 and CD40L. The TCR composition is also profoundly altered in lupus. Compared to normal T cells, the levels of CD3 f-chain (CD3f) are lower in lupus T cells, and this component is replaced by the Fce receptor common c-chain (FcRc), a component of the IgE receptor, which presents a structure similar to that of CD3f. This replacement is important because FcRc signals through a different adaptor protein, known as Syk, rather than via the intracellular protein zeta-associated protein 70 kd (1) .
In addition to these intrinsic structural disturbances that interfere with signal transduction between effector immune cells, the trafficking of these cells, as well as the secretion of mediators, can affect organelle homeostasis and cell metabolism in lupus (2) . Significant alterations of the mitochondrial, endolysosomal, and autophagosomal compartments have been documented (2) (3) (4) (5) (6) . These changes that modify the actual functioning of immune cells (e.g., ATP supply, life/death balance, impaired or excessive component elimination and recycling, and cell division, differentiation, and growth) are now known to occur in patients with SLE but are still far from being controlled appropriately by specific drugs.
As is generally the case in chronic, inflammatory autoimmune diseases, current pharmacologic treatments for SLE are largely palliative. Medications are focused on the dominant symptoms but do not address the defective pathways that are engaged in the lupus syndrome. In most patients, the drugs given for the treatment of SLE tend to result in nonspecific immunosuppression, which can be associated with disruption of innate and induced immunity, thereby aggravating the general health status of patients by generating significant adverse effects. Among the arsenal of medications that are under development, tools that target key components of the immune system, rather than those that globally reduce its hyperactivation, are still a rarity. Within this class of potent drugs, the phosphopeptide P140, which encompasses the sequence 131-151 of the U1-70K protein (7) , is very promising for treating patients with SLE (8) .
Following extensive studies in lupus-prone MRL/ lpr mice, we discovered that P140 targets autophagy (9), a finely orchestrated catabolic process involved in the regulation of inflammation and the biology of immune cells (10, 11) . P140 acts directly on a particular form of autophagy known as chaperone-mediated autophagy (CMA) (for more details, see ref. 12 ), which appears to be hyperactivated in MRL/lpr mouse B cells (9) , and most likely acts indirectly on the macroautophagy process (12, 13) , which also shows higher activity in both T and B cells in lupus (9, (13) (14) (15) (16) (17) . Shortly after its intravenous administration into MRL/lpr mice, the P140 peptide, which we followed up in the splenic B cells of MRL/lpr mice, was endocytosed via a clathrin-mediated endocytosis (CME) pathway and was found to accumulate in the lysosomes of these B cells that were acting as antigen-presenting cells (APCs). Noticeably, MRL/lpr mouse splenic lysosomes were unexpectedly found to exhibit some intrinsic defects; they especially displayed, on average, a significantly higher lumenal pH (9, 18) .
Supported by in vitro and in vivo studies carried out in MRL/lpr mice (7, 9, 13, (18) (19) (20) (21) , our current mechanistic view regarding the mode of action of P140 in MRL/lpr mice is as follows. The P140 peptide is known to readily interact with the constitutively expressed 70-kd heat-shock protein HSPA8 (22) . Once the peptide is internalized into B cell lysosomes, it could compromise abnormally activated CMA by disrupting the lysosomal HSPA8 heterocomplexes containing HSP90AA1 (13) . As a result, it is anticipated that cellular autoantigen loading to major histocompatibility complex (MHC) class II molecules in the late endosomal MHC class II compartments of B cell APCs would be altered, leading to a weaker priming of autoreactive T cells (19) and a probable reduction in the help signals to autoreactive B cells. These downstream events could contribute to the decrease in proliferation and differentiation of B cells into deleterious autoantibody-secreting plasma cells (ASPCs), resulting in a drop in autoantibody secretion (7) and a remarkable delay in mortality, as was found in P140-treated MRL/lpr mice compared to naive MRL/lpr mice that received saline only (7, 20) .
In a phase IIb multicenter, randomized, placebocontrolled clinical study of lupus, treatment with P140 (Lupuzor) was found to be safe and met its primary efficacy end points (8) , thus confirming the validity of the preclinical data generated in lupus-prone mice (7, 20) . At the moment, however, although it was found in the MRL/lpr mouse model of lupus, the effective influence of the P140 peptide on the function of APCs and T cells in human patients has not yet been addressed. Moreover, the potential effect of P140 on B cell differentiation has not been documented, even in a mouse setting.
To address these significant evidence gaps, we deciphered the effects of P140 using peripheral blood Peptides and peptide imaging. The phosphopeptides P140 (RIHMVYSKRpSGKPRGYAFIEY), truncated P140 desTyr 151 (RIHMVYSKRpSGKPRGYAFIE), and scrambled peptide ScP140 (YVSRYFGpSAIRHEPKMKIYRG), as well as the nonphosphorylated nominal peptide 131-151 (RIHM-VYSKRSGKPRGYAFIEY), were synthesized as described previously (7) . Their homogeneity was checked by analytic highperformance liquid chromatography (HPLC) and their identity was assessed by mass spectrometry. For coupling purposes, peptides were also synthesized with a cysteine residue added at their N-terminus. Alexa Fluor 488-conjugated Cys peptides were prepared by reacting equimolar amounts of the maleimide derivatives (ThermoFisher Scientific) and peptides in dimethylformamide. The conjugates were purified by HPLC and lyophilized in the dark. Fluorescence imaging of the peptides accumulating into lysosomes is described in detail in Supplemen- Evaluation of HLA molecule expression. Purified B cells (1 9 10 6 cells/ml) from healthy donors and SLE patients were incubated in complete culture medium. At 24 hours after incubation of the cells with peptides, expression of HLA molecules was evaluated by flow cytometry, using a fluorescein isothiocyanate-conjugated anti-HLA-DR/DP/DQ antibody.
Evaluation of macroautophagy and CMA levels by Western blotting and flow cytometry. The methods used to evaluate macroautophagy and the levels of CMA have been described recently (23) . The full experimental details are provided in Supplementary Patients and Methods (http://onlinelibrary.wiley. com/doi/10.1002/art.40470/abstract).
Toll-like receptor (TLR) ligand screening. The TLR ligand screening assay (InvivoGen) was based on recombinant HEK 293 cells, which stably express the functional human TLRs 2, 3, 4, 5, 7, 8, and 9 and an NF-jB-inducible reporter gene. Cells incubated with TLR-specific ligands were used as a positive control.
Statistical analysis. Statistical analyses were performed using GraphPad Prism software version 5.0. Depending on the number of samples that were included in the analyses, statistical significance was assessed using the parametric Student's t-test or the nonparametric Mann-Whitney U test. P values less than 0.05 were considered significant.
RESULTS
Peptide characteristics. The 21-mer P140 peptide corresponds to sequence 131-151 of the spliceosomal small nuclear RNP U1-70K. It contains a phosphoserine residue at position 140, which was added chemically during its synthesis when we undertook our first investigations on its potent protective properties in mice with lupus (7). It subsequently emerged that this punctual modification corresponded to a natural, apoptosis-specific posttranslational modification of the protein (24) . P140 alone (in saline or in mannitol) does not generate any antibody response in humans or in mice (21) . Its stability (and that of the phosphoryl moiety) has been analyzed at different temperatures and pH levels in various salt conditions and in controlled medium (9, 18) . The structure of both phosphorylated and nonphosphorylated sequences in aqueous solution has been determined by 1 H-nuclear magnetic resonance spectrometry and calculation of molecular dynamics (22) . P140, the sequence of which has been remarkably conserved over evolution, is a ligand of HSPA8; it interacts with the N-terminal nucleotide binding domain of the protein (9, 18) . It also promiscuously binds to murine and human MHC class II molecules in vitro and in vivo (7, 25) . In the present study, the first aspect that we explored in a human setting was to determine whether, as was observed in the context of lupusprone MRL/lpr mice, P140 uses CME as a portal to enter B cells, and whether it affects the expression of HSPA8 and HLA class II molecules at the surface of those cells.
Entry of P140 into human B cells by a clathrin coatdependent endocytosis process. In studies using markers of endocytosis and several cell-entry inhibitors that inhibit CME or caveolin-dependent endocytosis, we demonstrated that Alexa Fluor 488-labeled P140 readily entered human Raji B cells by CME, whereas the Alexa Fluor 488-labeled unphosphorylated peptide 131-151 and the truncated Alexa Fluor 488-labeled analog of peptide P140 entered human Raji B cells to a much lesser extent or not at all via CME ( Figures 1A-C and Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40470/abstract). In addition, the phosphopeptide P140 homed to lysosomes ( Figure 1D ). The same lysosomal accumulation of P140 was observed using B cells from healthy donors (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40470/abstract).
Collectively, our findings reveal the pathway used by the P140 peptide in human cells, and show the paramount importance of the phosphorylated moiety in this process. This set of experiments could not be performed using B cells from patients with SLE, due to the fact that only a low number of B cells could be purified from the PBMC fraction, as these patients are classically affected by lymphopenia.
Decreased overexpression of HLA class II molecules in the presence of P140 peptide. MHC class II molecules are overexpressed in MRL/lpr mouse splenic B cells, and we previously demonstrated that this overexpression was significantly diminished following daily intraperitoneal injections of P140 into 12-week-old mice (13) . Results from flow cytometry experiments confirmed that, as compared to healthy donor B cells, there was a significant increase in the levels of HLA-DR/DP/DQ molecules on SLE CD19+ B cells (P = 0.0056) but not on SSc CD19+ B cells (Figure 2A) . Treatment with P140, but not the ScP140 control peptide, significantly decreased, in a dose-dependent manner, the overexpression of HLA class II molecules on total CD19+ B cells ( Figure 2B ), regardless of whether the B cells were activated or were not activated (mean AE SD decrease À9.07 AE 6.07% and À11.13 AE 10.23%, respectively, at a P140 peptide concentration of 30 lM; P = 0.0004) (Figures 2C  and D) . This effect, however, had no influence on the absolute number or relative number (percentage) of activated B cells in the total B cell population (results not shown). Moreover, it was not linked to a possible apoptotic effect of P140 that could have affected B cells (see Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40470/abstract).
Of note, this abrogating effect of P140 on HLA-DR/DP/DQ overexpression was found to be related to individual scores on the SLE Disease Activity Index (SLEDAI) (26) in patients with SLE ( Figure 2E ). The higher the SLEDAI score in a patient, the stronger was Results are the mean AE SEM of triplicate experiments, from 3 independent experiments. D, B cell trafficking to lysosomes was evaluated using human Raji cells that were exposed to 10 lM Alexa Fluor 488-labeled peptides P140, 131-151, or ScP140 for 2 hours, followed by lysosomal staining with LysoTracker Red. Cells were washed and immediately imaged with a spinning disk microscope. Representative images from 2-3 independent experiments are shown. * = P < 0.05; **** = P < 0.0001 versus control, by Student's t-test. NS = not significant. the effect of P140 in terms of decreasing the expression of DR/DP/DQ molecules on the cell surface of CD19+ B cells. No direct relationship between the ex vivo effect of P140 and the levels of anti-double-stranded DNA (anti-dsDNA) antibodies was observed, thus indicating that the anti-dsDNA antibody is not a good marker of P140 efficacy.
It is also important to point out that treatment with P140 decreased, in a dose-dependent manner, the average expression of HLA class II molecules on B cells Relative expression values were normalized to that of untreated cells. In A-D, each symbol represents an individual patient or healthy donor; bars show the mean AE SD. * = P < 0.05; *** = P < 0.001; **** = P < 0.0001, by unpaired t-test. E, Correlation between decreased HLA-DR/DP/DQ expression on nonactivated CD19+CD86À B cells and the SLE Disease Activity Index (SLEDAI) score in patients with SLE (effect measured at a P140 concentration of 30 lM). Following Spearman's correlation analysis, patients with a negative score were excluded from the study. NS = not significant. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40470/abstract. 
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from healthy donors (mean AE SD decrease À15.4 AE 7.23%) ( Figure 3A) . However, the peptide had only a minimal effect on the average expression of HLA class II molecules on DCs from healthy donors (mean AE SD decrease À3.0 AE 17%) ( Figure 3B ). Whether P140 had a noticeable effect on DCs was, however, highly dependent on the individual healthy donor cell source. Autophagy in human B and T lymphocytes. Our earlier work showed that macroautophagy, the best-characterized type of autophagy, is abnormally enhanced in T lymphocytes from mice with lupus and patients with SLE (15). These results have been confirmed by others (16, 27) and supported by a recently completed study in B cells from (NZB 9 NZW)F1 mice and patients with lupus (17). Furthermore, macroautophagy was shown to be required for differentiation of plasmablasts (28, 29) and survival of memory B cells (30, 31) , thus indicating that this process seems to have a central role in humoral autoimmunity both in mice and in humans with lupus. In addition, our own studies demonstrated that CMA is also activated in MRL/ lpr mouse B cells (9) , and that this feature is associated with alteration of lysosomes, since the number and size, as well as average pH, of lysosomes were increased in our mouse model of lupus. In MRL/lpr mice that received P140 peptide intravenously, most of these alterations were no longer observed in B cells (9, 18) . Consistent with our own observations made in MRL/lpr mouse B cells (15) , no alteration of macroautophagy could be detected in human B cells in the present study ( Figures 4A and B) . This was measured by evaluating the intracellular expression of SQSTM1, which is selectively incorporated into autophagosomes and is degraded through macroautophagy (its cellular expression level negatively correlates with the activity of this process) (32) . As expected in these conditions, no effect of P140 was noted.
With regard to the effects on T cells, when compared to cells from healthy donors, the levels of SQSTM1 expression were found to be lower in CD4+ and CD8+ T cells from patients with SLE (as exemplified by the findings in 1 SLE patient shown in Figures 4C and E, and as found in 4 of the 5 SLE patients tested [ Figures 4D and  F] ). These results indicate that in contrast to B cells, Tcells display higher macroautophagy activity.
Active autophagic flux (determined as the conversion from MAP1LC3-I to MAP1LC3-II) could also be measured in phorbol myristate acetate/ionomycin-stimulated T cell cultures that were treated with the protease inhibitors E64D and pepstatin A or left untreated. No significant differences were found between healthy donor and SLE Tcells. In this cell type, no P140-dependent effect on the expression of MAP1LC3 or SQSTM1 could be observed ( Figures 4A-F CMA-associated markers were also studied in B and T cell subsets collected from the peripheral blood of healthy donors and patients with SLE; patients with SSc were used as controls. Both the expression of LAMP2A and expression of HSPA8 remained at the basal level in B cells and in resting or ex vivo-activated CD4+ and CD8+ T cells from all SLE blood donors examined (see Supplementary Figure 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40470/abstract). As expected in the absence of any specific activation of CMA in lymphocytes from patients with SLE, P140 showed no effect in this setting.
Lack of effect of P140 on TLR activation. Functional interactions between autophagy and pattern-recognition receptors, such as TLRs, nucleotide-binding oligomerization domain-containing protein-like receptors, and retinoic acid-inducible gene 1-like receptors, have been described (33) . Depending on the cell environment (e.g., cytokines/ chemokines) or on the cell subtype, these interactions with innate immunity receptors can functionally exert either activation or down-regulation of the autophagic machinery. Thus, induction of autophagy by signaling through TLRs 2, 3, 4, 5, and 7 has been described (34, 35) . With the current knowledge regarding the key role played by some TLRs, such as TLRs 4, 7, and 9, in lupus (36, 37) and the relationships that have been established between TLRs, autophagy, and lupus (35), we next determined whether P140 could interact with specific TLRs, particularly with endosomal TLRs 3, 7, 8, and 9. This possibility was tested using a screening assay based on recombinant HEK 293 cell lines expressing functional human TLRs, and an NF-jB-inducible reporter gene. P140 peptide was unable to activate any of the cell lines expressing human TLRs (see Supplementary Figure 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40470/ abstract), leading to the conclusion that, at least in the in vitro conditions used in the present study, P140 is not a TLR agonist.
To further consolidate these data, we studied the possible effect of P140 on the production of the proinflammatory cytokine tumor necrosis factor a (TNFa) by DCs collected from healthy donors. The antiinflammatory mannoside glycolipid conjugate 2U was used as an internal control (38) . The results showed that, in contrast to the effects of the 2U compound, P140 did not inhibit lipopolysaccharide-induced production of TNFa (see Supplementary Figure 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40470/abstract), thus further supporting the view that P140 has no effect on TLR-4 signaling.
Diminished proliferation of CD4+ T cells in the presence of P140-treated B cell APCs. We have demonstrated that P140 peptide readily reduces the expression of MHC class II molecules at the surface of B cells, both in human patients with SLE ( Figure 2 ) and mice with lupus (13) . We also showed previously in a lupus setting that P140 decreases the activity of self-reactive murine and human T cells (19, 25) . To determine whether these 2 functional events are directly linked, we developed a coculture system with B and T cells from distinct healthy donors, to induce an allogeneic response. B cells from healthy donor 1 were incubated with P140 at an optimal concentration of 30 lM (or with ScP140 as a control) or left untreated ( Figure 5A ). At this concentration, P140 induced a 20% decrease in the levels of MHC class II expression ( Figure 5B ). After treatment with mitomycin C, B cells were incubated with CD4+ T cells from the second healthy donor, at B cell:T cell ratios of 1:1 and 2:1. In this experimental setting, if a decrease in MHC class II expression is induced by P140, less antigenic peptides should be presented to T cells and, consequently, their proliferation in vitro should be diminished.
As expected, in the absence of any peptide, a significant increase in the percentage of CD4+CD25+ T cells (mostly corresponding to activated T cells) was continuously observed over time in the cocultures (Figure 5C ). In the presence of P140, however, CD4+ T cells proliferated significantly less actively (Figure 5D) . Reductions in the proliferation levels were most effective on days +4 and +5 of the coculture and at a B cell:T cell ratio of 2:1, as compared to a B cell:T cell ratio of 1:1. It was specific to P140, as no effect Figure 5 . Effect of peptide P140 on the capacity of CD4+ T cells to proliferate. A, Study design. In order to induce an allogeneic reaction, B and T cells from 2 different healthy donors were mixed at different B cell:T cell ratios. B, The most effective concentration of P140 to induce a significant decrease in major histocompatibility complex class II expression was evaluated, demonstrating that 30 lM of P140 was the optimal concentration. Each symbol represents an individual donor; bars show the mean AE SD (n = 10). ** = P < 0.01; **** = P < 0.0001, by unpaired t-test. C, Purified B cells incubated with 30 lM P140 for 24 hours were treated with mitomycin C (50 lg/ml, for 2 hours at 37°C) and mixed at different ratios with CD4+ T cells from a second donor. The efficacy of the coculture system was validated by measuring the percentage of CD4+CD25+ T cells over several days (D0-D5) of coculture. Results are the mean AE SD (n = 6). ** = P < 0.01 versus day 0, by Mann-Whitney U test. D, Proliferation of CD4+ T cells (measured as tritiated thymidine incorporation) was evaluated at 2 different cell ratios over several days of coculture without (w/o) peptide or with peptide P140 or ScP140. Results are the mean AE SEM from 5 independent experiments. * = P < 0.05; ** = P < 0.01; *** = P < 0.001, by Mann-Whitney U test. NS = not significant. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40470/abstract. was noted when B cells introduced into the coculture were pretreated with ScP140. These findings strongly suggest that the decrease in CD4+ T cell proliferation is a direct consequence of the diminished expression of MHC class II molecules and reduction in antigen presentation induced by the P140 peptide.
Prevention of B cell maturation and differentiation and reduced secretion of IgG following P140 treatment. Our previous results (13, 14, 19, 25) and the findings in the present study demonstrated that P140 induces a reduction in the level of expression of MHC class II molecules on B cell APCs and a lowering of T cell proliferation. We also showed previously, both in mice and in patients with lupus, that P140 in vivo administration leads to a reduction in the levels of blood circulating anti-dsDNA antibodies (7, 39) , which are markers of SLE. We therefore decided to conduct a set of experiments intended to determine a possible link between these 2 events, and in particular to examine whether, in conjunction with the effect of P140 on T cell activation, proliferation, and signaling ability, the drop in autoantibody secretion could be attributable to an altered capacity of B cells to differentiate into ASPCs. To check this ultimate property of P140, purified B cells from 5 healthy donors were allowed to differentiate in vitro with anti-CD40 antibodies, anti-IgM antibodies, and IL-21 (40) in the presence or absence of P140 peptide or control peptide ScP140. Six days later, B cell differentiation was assessed by flow cytometry to measure the expression of CD19, CD27, and CD38 ( Figure 6A) .
In a dose-dependent manner, P140, but not ScP140, decreased the percentage of CD19+CD27 high CD38 high plasma cells ( Figure 6B ). This finding was not linked to the apoptosis of B cells (results not shown), which can be a potential factor in 6-day cultures of B cells. Of note, the overall activation status of this depleted differentiated B cell population, as measured by CD86 marker expression, remained unchanged (Figures 6C and D) . However, the levels of IgG secreted by differentiated B cells in the supernatant of 8-day cultures was significantly decreased in the presence of P140 (at a concentration of 30 lM), but not in the presence of the ScP140 control peptide ( Figure 6E ).
Lack of a direct effect of P140 on BCR signaling of memory, naive mature, transitional, and B1 cells. In our last series of experiments, which were important to elaborate our working assumptions of the P140 mechanism of action in humans, we wanted to check whether P140 could display a direct effect on BCR signaling. These experiments were undertaken using a validated flow cytometry-based assay designed to investigate the BCR signaling pathway (Faludi M, et al: unpublished observations), a pathway that is critical in the development and function of B cells. Studying different B cell subtypes under multiple conditions revealed no effect of P140 and ScP140 peptides on BCR signaling in IgM memory, IgG memory, naive mature, transitional, or B1 cells (see Supplementary Figure 8 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40470/abstract).
Taken together, these whole series of data strongly support the view that P140 readily induces a drop in secretion of autoantibodies in patients with SLE via a mechanism involving the upstream step of T cell regulation (i.e., regulation of T cell activation, proliferation, and signaling ability) along with a strong downstream impact on B cell maturation and differentiation into ASPCs, but without directly acting on the maturation of B cells.
DISCUSSION
In the current study, which is the first to describe the molecular effect of therapeutic peptide P140 (Lupuzor) in human cells, we demonstrate that P140 has no direct effect on BCR signaling of memory, naive mature, or transitional B cells. This result suggests that P140 does not alter B cell survival and maturation through a direct effect on these B cell subsets. However, we clearly show that P140 is highly efficient at modulating the APC functions of B cells (in lupus, B cells, rather than DCs, play a central role in antigen presentation [see refs. 41 and 42] ). Ex vivo, P140 reduces the presentation of HLA class II molecules that are overexpressed on B cells from patients with SLE (but not patients with SSc). This P140-dependent decrease in HLA class II overexpression was directly related to the activity of lupus, as evaluated by the SLEDAI score. A similar effect was also visualized ex vivo on healthy donor B cells, but not on DCs collected from healthy volunteers.
The BCR studies required many experiments, and hence large numbers of B cells were needed for these studies. A sufficient number of B cells was not available from any lupus patient. If the BCR studies had been conducted on B cells from different lupus patients, the results would have been difficult to interpret, because the patients may have intrinsic differences in their BCR signaling. Therefore, these studies were carried out on B cells from a single patient without lupus. We are not aware of any therapy that affects BCR signaling exclusively in lupus patients.
In this study, we show that, as in MRL/lpr mice, P140 enters in human B cells by a clathrin coat-dependent endocytosis process and homes into lysosomes. Due to the lack of cell material, we were not able, in human SLE B cells, to demonstrate any alteration in macroautophagy or CMA processes with the use of classic markers of these pathways, nor were we able to raise any mechanistic conclusion regarding the possible effect of P140 on lysosome functioning in humans. However, using a combination of factors (anti-CD40 and anti-IgM antibodies in the presence of IL-21) to mimic T cell-driven B cell activation, expansion, and differentiation of normal B cells, we demonstrated very clearly that P140 down-regulates the maturation and differentiation of B cells into plasma cells and decreases IgG secretion by ASPCs.
Of important note, cells remaining after P140 treatment are fully active. If more cells from the peripheral blood of patients could become available, it would be interesting in this context to examine the capacity of P140 to interfere with activation, expansion, and differentiation of lupus B cells, with a particular emphasis on certain B cell subsets that are abnormally represented in patients with SLE, such as IgDÀCD27+ post-switched memory B cells (43) and another class of memory B cells that are IgDÀCD27À (44) . The elevated frequency of the latter B cell subset in the peripheral blood of patients with SLE has been reported to correlate with the extent of disease activity, especially with renal disease, and the occurrence of autoantibodies such as anti-native DNA and anti-Sm/RNP antibodies (45, 46) . The fact that P140 is potent at down-regulating the maturation and differentiation of human B cells into plasma cells is consistent with previous findings in mice with lupus, in which it was shown that the number of viable B220ÀCD138/syndecan 1+ plasma cells was decreased in the MRL/lpr mouse PBMC fraction after treatment with P140 peptide (22) .
A few cellular studies have been performed to assess alterations in autophagy in lymphocytes from lupus patients. These studies are converging toward the conclusion that macroautophagy is altered in T and B cells (15) (16) (17) 31) . In the present study using peripheral blood cells, we found no disease-related defect responsible for altering macroautophagy in these cell types (when assessed as conversion of MAPLC3-I to MAPLC3-II on Western blotting or as expression of SQSTM1 by flow cytometry), with the only exception, however, being CD4+ and CD8+ T cells, which, on average, expressed lower levels of SQSTM1 compared to healthy donor T cells. This hyperactivity of macroautophagy in circulating CD4+ and CD8+ Tcells was not rescued after ex vivo treatment with P140.
Future experiments with additional blood samples will clarify whether this observation reveals individual patient-related variations (due to their treatment or the stage, acute or quiescent, of the disease) or whether it could be attributed to a mechanistic feature with regard to, for example, specific cell subsets (including effector, memory, and regulatory T and B cells [see ref . 46] ), localization of the cells (in the blood versus tissue), levels of activation or anergy (47) and stress in the cells, or eventual lysosomal defects in the cells. The medication taken by patients (such as hydroxychloroquine) may also greatly affect the results visualized ex vivo. To our knowledge, CMA, which has been shown to be enhanced in mice with lupus (9), has not been examined previously in patients with SLE. In the present study, no change could be highlighted by evaluating the expression of the CMA markers LAMP2A and HSPA8 in flow cytometry analyses. At this stage, the lack of availability of large numbers of cells from patients limits certain investigations and, consequently, an important question remains regarding the fine mechanism through which HLA class II molecules are destabilized and through which antigen presentation to T cells is repressed.
In the absence of macroautophagy and CMA dysregulation, notably in B cells acting as APCs, any possible effect of P140 was obviously not visualized. Future experiments will focus on precisely pointing out these yet unsolved aspects, particularly when samples from patients with SLE who are included in the ongoing phase III multicenter, placebo-controlled clinical trial become available (before and after treatment) for our authorized ancillary study.
Overall, our findings provide clear evidence that the P140 peptide down-regulates B cell maturation and differentiation through a mechanism that does not involve the BCR directly, but rather originates upstream, from a P140-induced defect of signaling by T cells, which are themselves anergized or rendered inactive via a lack of activation by the HLA-peptide complex. This lack of activation after P140 treatment likely occurs as a result of destabilization or a defect in presentation of HLA class II molecules in B cell APCs, a feature that seems specific to B cells but not to other professional APCs such as DCs.
